Genome Canada’s Genomic Applications Partnership Program (GAPP) funds research and development projects that support public-private innovation. Each project involves collaborations between academic researchers and industry receptors—organizations positioned to apply research outcomes to address market opportunities or operational needs that have been identified by the private sector (these receptor organizations are hereafter referred to simply as “receptors”). These projects help leverage public investment in innovation, encourage industry investment in genomics and biotechnology research in Canada, and generate co-investment in market-driven research and development (R&D). They improve knowledge transfer from public institutions to Canadian companies to commercialize cutting-edge research and support our innovation value chain.

The Michael J. Fox Foundation for Parkinson’s Research, Therapeutics Pipeline Program: This program seeks to advance therapeutic development through pre-clinical and/or clinical testing of approaches addressing unmet needs of people with Parkinson’s disease (PD). The program is set up to benefit therapeutics with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms.

Funding will support projects aimed at:

• Pre-Clinical: Identifying, validating and/or developing novel pharmacological and non-pharmacological interventions through pre-clinical development from early screening to pre-clinical characterization and testing.

• Clinical: Progressing promising interventions with strong pre-clinical packages into/through initial clinical assessment exploring pharmacokinetics and pharmacodynamics, safety/tolerability, or early proof of biology and/or clinical efficacy. For novel targets, MJFF is particularly interested in de-risking programs by supporting early proof of concept in patients to gain insight into the therapeutic potential, including exploration of biomarker-based or clinical endpoint-based efficacy.

The Cancer Research Institute Clinical Innovator Grant supports pioneering immunotherapy clinical trials designed and led by academic researchers. These investigator-initiated studies are vital to improving patient outcomes, addressing areas of high unmet need, and generating critical mechanistic insights that can guide the future of cancer treatment.

The Weston Family Foundation invests in innovation and learning to deliver measurable impacts to the well-being of Canadians. We take a collaborative approach to philanthropy, working alongside forward-thinking partners to advance Canada and create lasting benefits.

GlycoNet is a one-stop global destination focused on developing new carbohydrate-based drugs, vaccines and diagnostics, in collaboration with academic and industry organizations to address areas of unmet need through applied glycomics research. This national platform supports translational research, protection of intellectual property, novel drug development, company formation and training of a new generation of glyco-scientists and entrepreneurs.

BioCanRx is a network of scientists, clinicians, cancer stakeholders, academic institutions, NGOs and industry partners working together to accelerate the development of leading edge immune oncology therapies for the benefit of patients. Their research pipeline funds projects in the proof of concept and preclinical development stages, into clinical trials and commercialization.

Since 1959, the Canadian Lung Association has funded research and research training to build capacity and to promote research that contributes to the field of respiratory health in Canada. We are proud to provide essential funding for everything from basic lab research to clinical trials to studies in lung disease prevention.

A key component of Breakthrough T1D’s research strategy is the support of clinical trials because they help advance work that has been tested extensively in the lab to testing in people. Breakthrough T1D holds numerous open funding calls for clinical trial research opportunities on an ongoing basis. Breakthrough T1D supports collaborative approaches, including between academic applicants and industry partners. Breakthrough T1D can assist industry applicants seeking an academic partner, or vice versa. Breakthrough T1D can also assist with regulatory considerations for interventions in this space.

Funding clinical trials worldwide across all cancer types, designed together with patient partners.